Posted by Michael Wonder on 21 May 2020
Health Canada grants market authorisation to Rozlytrek (entrectinib) for ROS1-positive, locally advanced or metastatic non-small cell lung cancer patients, not previously treated with crizotinib
20 May 2020 - Data show responses in 73% of patients who were treated with Rozlytrek.
Roche Canada is pleased to announce that Health Canada has granted market authorization to Rozlytrek (entrectinib) for the treatment of patients with ROS1-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC), not previously treated with crizotinib.
This new authorisation is based on an integrated analysis from three single-arm, open-label clinical trials evaluating Rozlytrek in the treatment of ROS1-positive advanced NSCLC adult patients, not previously treated with crizotinib.
